Search
Eluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalEluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). … Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms
Tinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLevoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.
Categories: Corticosteroids for Systemic UseAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnIt was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigationalEbola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Categories: Treatments for Ebola Virus DiseaseTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalBesides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Categories: Biologics for Rheumatoid Arthritis TreatmentCresol
go.drugbank.com/drugs/DB11143ApprovedAt concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized
Mixtures: Keloid Healer Synergy for treatment of keloidsEquine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.